(Adnkronos) - “Già disponibili da qualche anno in Italia hanno dimostrato grande efficacia nel trattamento dei segni e dei sintomi della malattia. Pensati per una gestione a lungo temine della patologia, con una sicurezza molto elevata, permettono al paziente di guadagnare in breve tempo una qualità di vita pressoché normale”.
Category
🗞
NewsTranscript
00:00The Italian experience with inhibitors in dermatitis topica and its comorbidities is
00:12quite dated today. In fact, it is a few years that we have these drugs available and the
00:18first thing that surprised us is the great effectiveness on dermatitis topica in relieving
00:24the patient first from the symptoms, i.e. pruritus and loss of sleep, and then almost completely
00:30clean the skin again, so the patient can regain a quality of life almost normal as
00:36if he did not have the disease. This quickly, already in the first 48 hours, the pruritus
00:42at least halves. Often the atopic patient is also affected by rhinitis, rhinitis conjunctivitis,
00:49asthma. Inhibitors at this time do not have the indication for these pathologies, but
00:55from our real life that we recently published in an accredited scientific journal, they
01:01still have an improvement of these comorbidities during the course of therapy with inhibitors.
01:08Studies in real life on the safety of inhibitors in dermatitis topica, but actually also
01:15in the other dermatological indications that we have today, for example alopecia areata, are
01:21very reassuring. In fact, the adverse events that we see more often are a slight increase
01:27in mild infections of the upper airway, i.e. cold, paringitis, which we also see, for
01:33example, with biologics, biological drugs for psoriasis, but which never lead to
01:39discontinuation of the drug. Another thing that can be seen is some recurrence of herpes, both
01:45herpes simplex and herpes zoster, which, however, can also be prevented with vaccination in
01:51more at-risk patients. We see transitory alterations of the hematochemical tests, of the
01:57hemochroma, of some indices of hepatic functionality, which, however, return quickly in the first
02:03weeks of therapy or with a slight modification of the dosage of the inhibitors that we have today.
02:09For most of the drugs to be used, we have two dosages, one a little lower,
02:15which has adverse events or particular characteristics, and another which is full dosage.
02:21So today I feel that the safety has been very high in clinical practice, selecting
02:27the patient well at the beginning.